Which Agent Best for Neuromyelitis Optica? : comparemela.com

A new indirect comparison of three new FDA-approved treatment options for aquaporin4+ neuromyelitis optica has suggested that eculizumab is the most effective. But many limitations have been raised.

Related Keywords

Minnesota , United States , Arizona , Mayo Clinic In Rochester , Oregon , Brian Weinshenker , Dennis Bourdette , Bruce Cree , Genentech , Department Of Neurology , Oregon Health Science University , Research In Multiple Sclerosis , University Of California San Francisco , European Committee For Treatment , European Committee , Multiple Sclerosis , Dean Wingerchuk , Mayo Clinic , Medscape Medical News , California San Francisco , Oregon Health , Science University , Multiple Sclerosis Journalthat , Multiple Sclerosis Ms , Us , Multiple Sclerosis Prognosis , S Prognosis , Ultiple Sclerosis Prognostic Factors , S Prognostic Factors , Primary Progressive Multiple Sclerosis , Pms , Immunosuppressive Therapy , Immunosuppressive Agents , Immunosuppressive Drugs , Rug Immunosuppressive , Relapsing Remitting Multiple Sclerosis , Arms , Ultiple Sclerosis Relapsing Remitting , Multiple Scl ,